Interstitial Lung Disease and Pulmonary Fibrosis: A Practical Approach for General Medicine Physicians with Focus on the Medical History
- PMID: 30477216
- PMCID: PMC6306719
- DOI: 10.3390/jcm7120476
Interstitial Lung Disease and Pulmonary Fibrosis: A Practical Approach for General Medicine Physicians with Focus on the Medical History
Abstract
Interstitial lung disease (ILD) and pulmonary fibrosis comprise a wide array of inflammatory and fibrotic lung diseases which are often confusing to general medicine and pulmonary physicians alike. In addition to the myriad of clinical and radiologic nomenclature used in ILD, histopathologic descriptors may be particularly confusing, and are often extrapolated to radiologic imaging patterns which may further add to the confusion. We propose that rather than focusing on precise histologic findings, focus should be on identifying an accurate etiology of ILD through a comprehensive and detailed medical history. Histopathologic patterns from lung biopsy should not be dismissed, but are often nonspecific, and overall treatment strategy and prognosis are likely to be determined more by the specific etiology of ILD rather than any particular histologic pattern. In this review, we outline a practical approach to common ILDs, highlight important aspects in obtaining an exposure history, clarify terminology and nomenclature, and discuss six common subgroups of ILD likely to be encountered by general medicine physicians in the inpatient or outpatient setting: Smoking-related, hypersensitivity pneumonitis, connective tissue disease-related, occupation-related, medication-induced, and idiopathic pulmonary fibrosis. Accurate diagnosis of these forms of ILD does require supplementing the medical history with results of the physical examination, autoimmune serologic testing, and chest radiographic imaging, but the importance of a comprehensive environmental, avocational, occupational, and medication-use history cannot be overstated and is likely the single most important factor responsible for achieving the best possible outcomes for patients.
Keywords: autoimmune; hypersensitivity; idiopathic pulmonary fibrosis; occupation; smoking.
Conflict of interest statement
The authors declare no conflict of interest related to this manuscript.
Figures




Similar articles
-
A comprehensive assessment of environmental exposures and the medical history guides multidisciplinary discussion in interstitial lung disease.Respir Med. 2021 Apr;179:106333. doi: 10.1016/j.rmed.2021.106333. Epub 2021 Feb 11. Respir Med. 2021. PMID: 33676119 Free PMC article.
-
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. Lancet Respir Med. 2020. PMID: 32145830 Clinical Trial.
-
Estimating the incidence of interstitial lung diseases in the Cree of Eeyou Istchee, northern Québec.PLoS One. 2017 Sep 8;12(9):e0184548. doi: 10.1371/journal.pone.0184548. eCollection 2017. PLoS One. 2017. PMID: 28886193 Free PMC article.
-
Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature.Autoimmun Rev. 2016 Jan;15(1):61-70. doi: 10.1016/j.autrev.2015.09.003. Epub 2015 Sep 16. Autoimmun Rev. 2016. PMID: 26384526 Review.
-
Diagnosis of interstitial lung diseases.Mayo Clin Proc. 2007 Aug;82(8):976-86. doi: 10.4065/82.8.976. Mayo Clin Proc. 2007. PMID: 17673067 Review.
Cited by
-
Drug-Induced Pulmonary Fibrosis: National Database Analysis.Biomedicines. 2024 Nov 21;12(12):2650. doi: 10.3390/biomedicines12122650. Biomedicines. 2024. PMID: 39767557 Free PMC article.
-
Transformation of macrophages into myofibroblasts in fibrosis-related diseases: emerging biological concepts and potential mechanism.Front Immunol. 2024 Sep 25;15:1474688. doi: 10.3389/fimmu.2024.1474688. eCollection 2024. Front Immunol. 2024. PMID: 39386212 Free PMC article. Review.
-
Exploring the common pathophysiological links between IPF, SSc-ILD and post-COVID fibrosis.Lung India. 2022 May-Jun;39(3):279-285. doi: 10.4103/lungindia.lungindia_89_22. Lung India. 2022. PMID: 35488687 Free PMC article. Review.
-
Involvement of the ACE2/Ang-(1-7)/MasR Axis in Pulmonary Fibrosis: Implications for COVID-19.Int J Mol Sci. 2021 Nov 30;22(23):12955. doi: 10.3390/ijms222312955. Int J Mol Sci. 2021. PMID: 34884756 Free PMC article. Review.
-
Interferon-λ3 rs12979860 can regulate inflammatory cytokines production in pulmonary fibrosis.Saudi Pharm J. 2023 Nov;31(11):101816. doi: 10.1016/j.jsps.2023.101816. Epub 2023 Oct 6. Saudi Pharm J. 2023. PMID: 37876736 Free PMC article.
References
-
- American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 2002;165:277–304. doi: 10.1164/ajrccm.165.2.ats01. - DOI - PubMed
-
- Travis W.D., Costabel U., Hansell D.M., King T.E.J., Lynch D.A., Nicholson A.G., Ryerson C.J., Ryu J.H., Selman M., Wells A.U., et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 2013;188:733–748. doi: 10.1164/rccm.201308-1483ST. - DOI - PMC - PubMed
-
- Bradley B., Branley H.M., Egan J.J., Greaves M.S., Hansell D.M., Harrison N.K., Hirani N., Hubbard R., Lake F., Millar A.B., et al. Interstitial lung disease guideline: The British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63(Suppl. 5):v1–v58. - PubMed
-
- Raghu G., Collard H.R., Egan J.J., Martinez F.J., Behr J., Brown K.K., Colby T.V., Cordier J.-F., Flaherty K.R., Lasky J.A., et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011;183:788–824. doi: 10.1164/rccm.2009-040GL. - DOI - PMC - PubMed
-
- Raghu G., Rochwerg B., Zhang Y., Garcia C.A.C., Azuma A., Behr J., Brozek J.L., Collard H.R., Cunningham W., Homma S., et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am. J. Respir. Crit. Care Med. 2015;192:e3–e19. doi: 10.1164/rccm.201506-1063ST. - DOI - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources